Department of Pathology, Zhongnan Hospital of Wuhan University, Wuhan, P. R. China.
Department of Pathology, School of Basic Medical Sciences, Wuhan University, Wuhan, P. R. China.
PLoS One. 2024 Nov 14;19(11):e0313561. doi: 10.1371/journal.pone.0313561. eCollection 2024.
Breast cancer (BRCA) is among the most prevalent cancers and is responsible for numerous patient fatalities. Immunotherapy has emerged as a promising approach to cancer treatment. Recent studies have identified Siglec-15 as a novel immune target that plays a crucial role in tumor immune evasion, suggesting its potential significance in BRCA. We utilized databases such as TCGA to investigate the relevance of SIGLEC15 in BRCA. The expression of the Siglec-15 protein in 74 breast cancer patients was detected using immunohistochemistry, and its association with clinicopathological features and overall survival was evaluated. The co-expression of Siglec-15, CD68, CK, and CD8 in BRCA tissues was identified through multiplex immunofluorescence staining. Our study revealed that SIGLEC15 expression in BRCA was significantly elevated compared to adjacent normal tissues. Kaplan-Meier analysis identified SIGLEC15 as a prognostic protective factor. According to the receiver operating characteristic curve analysis, SIGLEC15 could predict the luminal subtype of BRCA. Enrichment analysis demonstrated that SIGLEC15 involves various biological pathways, including immunity, metabolism, tumors, and infectious diseases. Correlation analysis revealed an association between SIGLEC15 expression and immune infiltration in BRCA. We also confirmed that the Siglec-15 protein is expressed in cancer cells, tumor-infiltrating T cells, and macrophages in BRCA tissues, significantly higher levels than in normal breast tissues. Consequently, SIGLEC15 correlates with tumor immune infiltration, molecular subtypes, and BRCA progression and prognosis. However, further research is required to elucidate the role of SIGLEC15 in breast cancer.
乳腺癌（BRCA）是最常见的癌症之一，也是许多患者死亡的原因。免疫疗法已成为癌症治疗的一种有前途的方法。最近的研究表明 Siglec-15 是一种新型免疫靶点，在肿瘤免疫逃逸中发挥关键作用，表明其在 BRCA 中的潜在意义。我们利用 TCGA 等数据库研究了 SIGLEC15 在 BRCA 中的相关性。使用免疫组织化学检测了 74 例乳腺癌患者中 Siglec-15 蛋白的表达，并评估了其与临床病理特征和总生存期的关系。通过多重免疫荧光染色鉴定了 BRCA 组织中 Siglec-15、CD68、CK 和 CD8 的共表达。我们的研究表明，与相邻正常组织相比，BRCA 中的 Siglec-15 表达明显升高。Kaplan-Meier 分析确定 SIGLEC15 是一个预后保护因素。根据接收者操作特征曲线分析，SIGLEC15 可以预测 BRCA 的腔型亚型。富集分析表明，SIGLEC15 涉及多种生物学途径，包括免疫、代谢、肿瘤和传染病。相关性分析显示 Siglec-15 表达与 BRCA 中的免疫浸润之间存在相关性。我们还证实 Siglec-15 蛋白在 BRCA 组织中的癌细胞、肿瘤浸润性 T 细胞和巨噬细胞中表达，明显高于正常乳腺组织。因此，SIGLEC15 与肿瘤免疫浸润、分子亚型以及 BRCA 的进展和预后相关。然而，需要进一步的研究来阐明 SIGLEC15 在乳腺癌中的作用。
